MesoblastASX:MSB +0.49%46 14-Day RSI is 51.09 as of Jul. 05, 2026. GuruFocus rates ASX:MSB with a GF Score™ of 46/100. The stock has 4 warning signs investors should review. Among 1,423 Biotechnology companies, Mesoblast ranks worse than 51.86% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-05), Mesoblast's 14-Day RSI is 51.09.
The industry rank for Mesoblast's 14-Day RSI or its related term are showing as below:
ASX:MSB's 14-Day RSI is ranked worse than 51.86% of 1423
companies
in the Biotechnology industry
Industry Median: 49.99
vs ASX:MSB: 51.09
Mesoblast (ASX:MSB) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Mesoblast 14-Day RSI Related Terms
ASX:MSB vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, Mesoblast's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mesoblast 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mesoblast's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Mesoblast's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mesoblast (ASX:MSB) has a 14-Day RSI of 51.09 as of Jul. 05, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Mesoblast and its competitors. According to the industry distribution chart, Mesoblast ranks #738 out of 1423 companies in the Biotechnology industry, placing it in the top 51.9%.
Is Mesoblast's 14-Day RSI too high?
Mesoblast's current 14-Day RSI is 51.09. The Biotechnology industry median 14-Day RSI is 49.99. Mesoblast's value of 51.09 is 2.2% above this industry median. Based on the distribution chart, Mesoblast ranks #738 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Mesoblast has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mesoblast ranks #738 out of 1423 companies for 14-Day RSI. This places Mesoblast in the lower half of its industry. The industry median 14-Day RSI is 49.99. Mesoblast's value of 51.09 is 2.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 49.99, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mesoblast's current 14-Day RSI of 51.09 is 2.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Mesoblast and its competitors. For the Biotechnology industry, the median 14-Day RSI is 49.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mesoblast's current 14-Day RSI is 51.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current 14-Day RSI of 51.09. The current 14-Day RSI is 51.09 and 2.2% above the Biotechnology industry median of 49.99. Mesoblast's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current 14-Day RSI is 51.09 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
46GF Score
Get the complete analysis for ASX:MSB
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MSB has been successfully added to your 